The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study-Reference-Cited by-同舟云学术

The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study

Published:2022-08-12 Issue: Volume: Page:
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Guven Deniz Can,Yekeduz Emre,Erul Enes,Yazgan Sati Coskun,Sahin Taha Koray,Karatas Gokturk,Aksoy Sercan,Erman Mustafa,Yalcin Suayib,Urun Yuksel,Kilickap Saadettin

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-022-04268-8.pdf

Reference47 articles.

1. Beaver JA, Hazarika M, Mulkey F et al (2018) Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. Lancet Oncol 19(2):229–239. https://doi.org/10.1016/s1470-2045(17)30846-x

2. Benavente S, Sánchez-García A et al (2020) Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies. Frontiers in Oncology. https://doi.org/10.3389/fonc.2020.582884

3. Bennouna J, Sastre J, Arnold D et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14(1):29–37. https://doi.org/10.1016/s1470-2045(12)70477-1

4. Borcoman E, Kanjanapan Y, Champiat S et al (2019) Novel patterns of response under immunotherapy. Ann Oncol 30(3):385–396. https://doi.org/10.1093/annonc/mdz003

5. Budimir N, Thomas GD, Dolina JS, Salek-Ardakani S (2022) Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade. Cancer Immunol Res 10(2):146–153. https://doi.org/10.1158/2326-6066.Cir-21-0515

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data;Journal of Cancer Research and Clinical Oncology;2024-03-18

2. Concomitant Immunotherapy and Metastasis-Directed Radiotherapy in Upper Tract Urothelial Carcinoma: A Biomarker-Driven, Original, Case-Based Proof-of-Concept Study;Journal of Clinical Medicine;2023-12-18

3. Early thrombocytopenia predicts longer time‑to‑treatment discontinuation in trastuzumab emtansine treatment;Oncology Letters;2023-10-23